

# Dual RMCE for efficient re-engineering of mouse mutant alleles

Marco Osterwalder<sup>1</sup>, Antonella Galli<sup>1,3</sup>, Barry Rosen<sup>2</sup>, William C Skarnes<sup>2</sup>, Rolf Zeller<sup>1</sup> & Javier Lopez-Rios<sup>1</sup>

**We have developed dual recombinase-mediated cassette exchange (dRMCE) to efficiently re-engineer the thousands of available conditional alleles in mouse embryonic stem cells. dRMCE takes advantage of the wild-type *loxP* and *FRT* sites present in these conditional alleles and in many gene-trap lines. dRMCE is a scalable, flexible tool to introduce tags, reporters and mutant coding regions into an endogenous locus of interest in an easy and highly efficient manner.**

Gene targeting by homologous recombination in mouse embryonic stem cells is a powerful tool for tailored manipulation of the mouse genome. However, the efficiency of this technology is limited by the great variation in targeting frequencies for different loci<sup>1</sup>. In particular, targeting frequencies for a substantial number of loci are very low (<1%), which renders repeated genetic manipulation tedious, especially as the screening strategy usually involves Southern blotting or long-range PCR. In light of the increasing need to re-engineer more subtle mutations at the same locus, recombinase-mediated cassette exchange (RMCE; reviewed in ref. 2) was developed to facilitate this process. RMCE takes advantage of pairs of heterotypic, noninteracting recombination sites for a particular site-specific recombinase, but these sites first need to be introduced into the locus of interest through conventional homologous recombination. Subsequently, co-transfection of such modified mouse embryonic stem cells with the custom-designed RMCE exchange vector and the appropriate recombinase expression plasmid will result in replacement at the endogenous locus<sup>2</sup>.

It was previously established that coexpression of both Cre and Flp recombinases catalyzes the exchange of sequences flanked by single *loxP* and *FRT* sites (their respective standard target sites) integrated into the genome at a random location<sup>3</sup>. However, this study did not explore whether such an approach could be used to modify conditional mouse alleles carrying single or multiple *loxP* and *FRT* sites. Therefore, we decided to develop dual RMCE (dRMCE) as a re-engineering tool applicable to the vast numbers of mouse conditional alleles that harbor wild-type *loxP* and *FRT* sites and therefore are not compatible with conventional


RMCE. In particular, dRMCE will expand the long-term value of the rapidly increasing collection of targeted alleles produced by the International Knockout Mouse Consortium (IKMC; <http://www.knockoutmouse.org/>). This large-scale program is generating 'knockout-first' conditional alleles for most protein-coding genes in mouse embryonic stem cells, and several thousand alleles are already available<sup>4</sup>.

The general dRMCE strategy takes advantage of the fact that most conditional alleles encode a selection cassette flanked by *FRT* sites, in addition to *loxP* sites that flank functionally relevant exons ('floxed' exons; **Fig. 1a**). The *FRT*-flanked selection cassette is in general placed outside the *loxP*-flanked region, which renders these alleles directly compatible with dRMCE. Simultaneous expression of Cre and Flp recombinases should rapidly induce *cis* recombination and formation of the deleted allele, which would then serve as a 'docking site' at which to insert the replacement vector by *trans* recombination (**Fig. 1a**). The correctly replaced locus would encode the custom modification and a different drug-selection cassette flanked by single *loxP* and *FRT* sites.

In developing dRMCE, we used optimized versions of the Cre (iCre)<sup>5</sup> and Flp (Flpo)<sup>6</sup> recombinases to assemble the pDIRE expression vector (see **Supplementary Fig. 1a** and **Supplementary Data** for complete vector sequences). We also developed the pDREV vector series (**Supplementary Fig. 1b** and **Supplementary Data**) that allows insertion and efficient expression of reporters and/or coding regions of choice in any IKMC knockout-first allele. We tested the feasibility of dRMCE-mediated replacement using loci representing these readily available knockout-first alleles as well as standard conditional loss-of-function mutations generated by individual researchers.

The floxed *Smad4* (*Smad4<sup>f</sup>*) knockout-first allele generated by the IKMC contains a promoterless gene-trap selection cassette (*lacZ-T2A-neo*) that is flanked by *FRT* sites and followed by *loxP* sites flanking a critical *Smad4* coding exon (**Fig. 1b**). This results in expression of a *lacZ* reporter and the neomycin resistance (*neo*) genes under control of the endogenous *Smad4* promoter, which is active in embryonic stem cells. Heterozygous *Smad4<sup>f</sup>* mouse embryonic stem cells were co-transfected with the pDIRE and pDREV-1 vectors, the latter of which encodes an *H2B-Venus YFP* reporter (**Fig. 1b**). Puromycin-resistant colonies were screened by short-range PCR at the 3' (*loxP*) and the 5' (*FRT*) junctions for correct replacement events, which resulted in the *YFP*-tagged *Smad4* allele (*Smad4<sup>YFP</sup>*; **Fig. 1c**). Most of the colonies were correctly replaced and of clonal origin (69%: 33 out of 48 clones; **Supplementary Table 1**). In contrast to the  $\beta$ -galactosidase-positive *Smad4<sup>f</sup>* cells (**Fig. 1d**), *Smad4<sup>YFP</sup>* colonies have lost the *lacZ* reporter and have become YFP positive (**Fig. 1e,f**).

<sup>1</sup>Developmental Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland. <sup>2</sup>The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK. <sup>3</sup>Present address: Department of Medicine and Genetics & Development, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York, USA. Correspondence should be addressed to J.L.-R. ([javier.lopez-rios@unibas.ch](mailto:javier.lopez-rios@unibas.ch)) or R.Z. ([rolf.zeller@unibas.ch](mailto:rolf.zeller@unibas.ch)).



**Figure 1** | The principle of dRMCE to re-engineer mouse conditional alleles. (a) Schematic of the target locus shows the configuration of a conditional mouse allele with a genomic region flanked by two *loxP* sites and an outside selection cassette flanked by two *FRT* sites. Upon transfection, the combination of iCre- and Flpo-mediated recombination in *cis* results in a deleted allele flanked by single *loxP* and *FRT* sites, which serves as a 'docking site' for insertion of the replacement vector. ex, exon.

(b) Schematic representation of replacement in the *Smad4* locus by dRMCE. The target locus is a *Smad4* conditional allele (*Smad4<sup>f</sup>*) with a promoterless selection cassette. Co-transfection of the pDIRE and pDREV-1 plasmids induces replacement, probably through production of the *Smad4<sup>-</sup>* deleted allele as intermediate. Correct *trans* insertion of the replacement vector results in the *Smad4<sup>YFP</sup>* allele. F1–F4 and R1–R3 denote primers used for PCR screening of colonies (see **Supplementary Table 2** for sequences). H2B-Venus, YFP fusion protein with histone 2B; *lacZ*,  $\beta$ -galactosidase coding region; *neo*, neomycin resistance coding region; *puro*, puromycin resistance cassette; *rox*, Dre recombinase target sites<sup>11</sup>; SA, splice acceptor; T, autocleavable T2A peptide coding region<sup>14</sup>. (c) PCR screening reveals a large number of clones with correct 3' and 5' replacement (69%). Col, colony; 3' recombination, 5' recombination, correct replacement at the 3' and 5' ends, respectively. (d) The parental *Smad4<sup>f</sup>* cells are  $\beta$ -galactosidase positive. (e, f) Clones with correct replacement (*Smad4<sup>YFP</sup>*) lack  $\beta$ -galactosidase activity but show YFP fluorescence. (g) Micrograph shows single cells expressing the H2B-Venus fusion protein engineered by dRMCE. Scale bars: 100  $\mu$ m (d–f), 5  $\mu$ m (g).

The H2B-Venus fusion protein appeared to be functional, as it was nuclear and bound to chromosomes during mitosis (**Fig. 1g**)<sup>7</sup>.

A small number of colonies were mixed, as judged by PCR analysis (**Fig. 1c** and **Supplementary Table 1**). These mixed colonies were easily recognized because they were composed of cells positive for either  $\beta$ -galactosidase activity (*Smad4<sup>f</sup>* allele) or YFP fluorescence (*Smad4<sup>YFP</sup>* allele) but not both (**Supplementary Fig. 2**). Some other mixed colonies contained cells carrying the *Smad4* loss-of-function allele (*Smad4<sup>-</sup>*; **Fig. 1c** and **Supplementary Fig. 2**). This analysis indicated that mixed colonies originate as a consequence of incomplete recombination. Therefore, dRMCE-mediated replacement must always be validated by confirming the absence of both the floxed and the deleted allele.


The floxed *Zfp503* (*Zfp503<sup>f</sup>*) knockout-first allele from the IKMC encodes a promoter-driven selection cassette and three *loxP* and two *FRT* sites (**Supplementary Fig. 3a**). We co-transfected recipient heterozygous *Zfp503<sup>f</sup>* mouse embryonic stem cells with the pDIRE and pDREV-0 plasmids and selected colonies on the basis of their resistance to puromycin. Generation of the correctly replaced YFP-tagged *Zfp503* (*Zfp503<sup>YFP</sup>*) allele was again highly efficient (52%; **Supplementary Fig. 3b** and **Supplementary Table 1**).

To establish dRMCE as a universally applicable method for re-engineering of conditional alleles, we also targeted two other loci. We first selected the *Hand2* locus, as it is very difficult to target by homologous recombination (0.17%)<sup>8</sup>, and chose to use dRMCE to introduce a Flag epitope tag into the endogenous *Hand2* coding region (*Hand2<sup>Flag</sup>*). To this end, we co-transfected mouse embryonic stem cells heterozygous for the floxed *Hand2* (*Hand2<sup>f</sup>*) allele with the pDIRE and a pDRAV-type *Hand2<sup>Flag</sup>* replacement vectors (**Fig. 2a** and **Supplementary Fig. 1**). Molecular analysis revealed that 13% of all drug-resistant colonies had undergone correct replacement (**Fig. 2b** and **Supplementary Table 1**). Second, we carried out dRMCE-mediated replacement of a *Gli3* conditional allele (J.L.-R. and

R.Z., unpublished data) with the *Hand2<sup>Flag</sup>* vector, resulting in 33% correct replacement (**Supplementary Table 1** and data not shown). These results indicate that dRMCE permits highly efficient re-engineering of conditional alleles with wild-type *loxP* and *FRT* sites in one step, irrespective of the difficulty of targeting the parental locus by homologous recombination.

To assess the potential effects of dRMCE on germline transmission, we injected two correctly engineered *Hand2<sup>Flag</sup>* mouse embryonic stem cell clones (**Supplementary Fig. 4**) separately into mouse blastocysts, which resulted in several highly chimeric offspring in each case (80–100% as judged by coat color). These chimeric males transmitted the *Hand2<sup>Flag</sup>* allele to their F<sub>1</sub> progeny within the first two litters (**Fig. 2c**). These results indicated that dRMCE neither compromises germline transmission potential nor causes frequent chromosomal abnormalities, as judged by karyotyping of all clones<sup>9</sup> before injection (data not shown). Furthermore, the mouse embryonic stem cells used by the IKMC to generate their conditional alleles have been proven to remain highly germline competent even after multiple rounds of gene targeting and exposure to site-specific recombinases<sup>10</sup>.

Most notably, dRMCE-mediated engineering did not alter the temporal and spatial expression of *Hand2* transcripts in mouse embryos homozygous for the *Hand2<sup>Flag</sup>* allele (**Fig. 2d** and **Supplementary Fig. 5**). The *Hand2<sup>Flag</sup>* allele was fully functional, as homozygous embryos and mice were phenotypically wild type, which contrasts with the lethality of *Hand2*-deficient mouse embryos<sup>8</sup>. In summary, dRMCE allowed re-engineering of conventional targeted alleles with frequencies of 10–70% correct replacement (**Table 1**). Minimally, this represented a 5- to 65-fold increase in efficiency in comparison to homologous recombination, which is particularly beneficial for difficult to target loci. Even at the lowest efficiency (13% for *Hand2*, **Table 1**), very few colonies needed to be analyzed to identify correctly replaced clones (for example, one 48-well plate of colonies).



**Figure 2** | dRMCE for efficient modification of difficult-to-target loci. **(a)** Schematic shows the conditional *Hand2* allele (*Hand2*<sup>f</sup>) used as a target locus for insertion of a Flag epitope tag into the *Hand2* coding region. After co-transfection of the replacement vector (pRVH2) and pDIRE plasmid into heterozygous *Hand2*<sup>f</sup> mouse embryonic stem cells, dRMCE-mediated replacement results in the *Hand2*<sup>Flag</sup> allele. The PGK-*hygro* (hygromycin resistance gene) selection cassette is flanked by the *attB* and *attP* target sites for excision by the  $\phi$ C31 recombinase. F5–F7 and R5–R7 denote primers used for PCR screening and genotyping. E, EcoRV site required to detect correct 5' replacement by combining PCR amplification with an EcoRV restriction digestion. **(b)** PCR screening at both ends of the locus identified *Hand2* colonies with correct replacement (13%). Scheme at right shows PCR fragment patterns indicative of particular genomic configurations. 3' recombination, 5' recombination, correct replacement at the 3' and 5' ends, respectively. A, B, primers to amplify a region serving as positive control (see **Supplementary Table 2** for sequences). **(c)** Gels show germline transmission of the *Hand2*<sup>Flag</sup> allele (lanes 1, 5, 6). Above, PCR analysis to detect *Hand2*<sup>Flag</sup> allele. Below, PCR detection of wild-type allele. **(d)** *In situ* detection of *Hand2* transcripts in a wild-type (*Hand2*<sup>+/+</sup>; left) and *Hand2*<sup>Flag/Flag</sup> (right) mouse embryo at embryonic day 10.5. Note expression in the posterior limb bud mesenchyme (arrow), branchial arches (black arrowhead) and heart (white arrowhead). Scale bar, 500  $\mu$ m.

To facilitate the generation of dRMCE targeting vectors for the large number of alleles containing both *loxP* and *FRT* sites (**Fig. 1a**), we prepared a tool kit consisting of the pDIRE expression vector and various dRMCE vectors (**Supplementary Fig. 1** and **Supplementary Data**). In all cases, the selection cassette can be removed either in cells or directly in mice by breeding them to Dre<sup>11</sup> or  $\phi$ C31o<sup>6</sup> deleter mouse strains. The vector backbones allow the use of validated vector-specific primers for PCR screening in combination with locus-specific primers (**Supplementary Table 2**).

Taken together, our data indicate that dRMCE is a highly efficient and universal tool for re-engineering of conditional mouse alleles. dRMCE also provides a one-step alternative to the Floxin strategy<sup>12</sup> recently developed for gene trap lines available from the International Gene Trap Consortium (IGTC; <http://www.genetrapp.org/>)<sup>13</sup>. dRMCE is conceptually straightforward and allows a wide range of precise genomic modifications to be engineered. For example, dRMCE can be used to express mutant gene products and introduce epitope or fluorescent tags or heterologous genes into the endogenous locus of choice. Because of its efficiency, the dRMCE technology is well suited for high-throughput approaches such as functional screening of disease-causing mutations in pathways or genes of interest directly in mouse embryonic stem cells (for example, upon induced differentiation into specific cell types) or in mice generated from engineered clones. Finally, dRMCE technology provides nonspecialists with access to advanced mouse genetic engineering and enhances the long-term value of the existing large collections of genetically altered mouse embryonic stem cell lines.

**Table 1** | dRMCE allows re-engineering of different loci at frequencies much higher than homologous recombination

Gene locus	dRMCE	Homologous recombination	Fold increase
<i>Smad4</i>	69%	6% <sup>15</sup>	12 $\times$
<i>Zfp503</i>	52%	11% <sup>a</sup>	5 $\times$
<i>Hand2</i>	13%	0.2% <sup>8</sup>	65 $\times$
<i>Gli3</i>	33%	3% <sup>b</sup>	11 $\times$

<sup>a</sup>IKMC. <sup>b</sup>Unpublished.

## METHODS

Methods and any associated references are available in the online version of the paper at <http://www.nature.com/naturemethods/>.

Note: Supplementary information is available on the Nature Methods website.

## ACKNOWLEDGMENTS

We are grateful to D. Klewe-Nebenius and T. Hennek (University of Basel) for generating the chimeric mice. We thank I. Verma (Salk Institute, San Diego, California, USA), B. Sauer (Stowers Institute, Kansas City, Missouri, USA), R. Jaenisch (Whitehead Institute, Cambridge, Massachusetts, USA) and P. Soriano (Mount Sinai School of Medicine, New York, New York, USA) for plasmids obtained via Addgene and A.-K. Hadjantonakis (Sloan-Kettering Institute, New York, New York, USA) for suggesting the use of the H2B-Venus fusion protein. We thank A. Schauerte and P. Lorentz for expert technical assistance and are indebted to P. Bovolenta, G. Nusspaumer, A. Zuniga and members of our research groups for helpful input and discussions. Our research is supported by the Swiss National Science Foundation (to R.Z.), by a Marie Curie Intra-European Fellowship and a European Reintegration Grant (to J.L.-R.) and by both cantons of Basel, Switzerland.

## AUTHOR CONTRIBUTIONS

M.O., J.L.-R. and R.Z. conceived and designed the experiments. M.O., J.L.-R. and B.R. designed and constructed the dRMCE tool-kit vectors. B.R. and W.C.S. provided the IKMC mouse embryonic stem cell lines. M.O., A.G., J.L.-R. and B.R. performed the experiments. J.L.-R., W.C.S. and R.Z. wrote the paper.

## COMPETING FINANCIAL INTERESTS

The authors declare competing financial interests: details accompany the full-text HTML version of the paper at <http://www.nature.com/naturemethods/>.

Published online at <http://www.nature.com/naturemethods/>.

Reprints and permissions information is available online at <http://npg.nature.com/reprintsandpermissions/>.

- Glaser, S., Anastassiadis, K. & Stewart, A.F. *Nat. Genet.* **37**, 1187–1193 (2005).
- Brandt, C.S. & Dymecki, S.M. *Dev. Cell* **6**, 7–28 (2004).
- Lauth, M., Spreafico, F., Dethleffsen, K. & Meyer, M. *Nucleic Acids Res.* **30**, e115 (2002).
- Collins, F.S., Rossant, J. & Wurst, W. *Cell* **128**, 9–13 (2007).
- Shimshak, D.R. *et al. Genesis* **32**, 19–26 (2002).
- Raymond, C.S. & Soriano, P. *PLoS ONE* **2**, e162 (2007).
- Kanda, T., Sullivan, K.F. & Wahl, G.M. *Curr. Biol.* **8**, 377–385 (1998).
- Galli, A. *et al. PLoS Genet.* **6**, e1000901 (2010).
- Nagy, A. *Manipulating the Mouse Embryo: A Laboratory Manual* 3rd edn. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, USA, 2003).
- Pettitt, S.J. *et al. Nat. Methods* **6**, 493–495 (2009).
- Anastassiadis, K. *et al. Dis. Model. Mech.* **2**, 508–515 (2009).
- Singla, V. *et al. Nat. Methods* **7**, 50–52 (2010).
- Skarnes, W.C. *et al. Nat. Genet.* **36**, 543–544 (2004).
- Szymczak, A.L. *et al. Nat. Biotechnol.* **22**, 589–594 (2004).
- Chu, G.C., Dunn, N.R., Anderson, D.C., Oxburgh, L. & Robertson, E.J. *Development* **131**, 3501–3512 (2004).

## ONLINE METHODS

**dRMCE protocols and plasmids.** The step-by-step protocols used for dRMCE are available online through the Nature Protocols Network (<http://www.natureprotocols.com/>). All dRMCE plasmids are available from the Addgene repository (<http://www.addgene.org/>).

**Construction of the pDIRE expression vector.** The *iCre* coding sequence was amplified by PCR from the pBOB-CAG-*iCre*-SD plasmid (Addgene) using primers with specific restriction sites. After digestion with *Sall* and *NotI*, the *iCre* fragment was cloned into pBluescript IKS (Stratagene). The human *EF1A* promoter was later inserted 5' as a *HindIII*-*BamHI* fragment derived from the pBS513 *EF1alpha-Cre* plasmid (Addgene). The SV40 polyadenylation (SV40 pA) site was inserted as a *SpeI*-*SpeI* fragment after PCR amplification from the pEGFP-N1 plasmid. These cloning steps resulted in the p*EF1α-iCre* cassette, which was completely sequenced. This *iCre* expression unit was isolated as an *EcoRV*-*EcoRV* fragment and inserted into the *PsiI* site of the pPGK*FlpobpA* plasmid (Addgene) to generate the pDIRE expression vector (Supplementary Fig. 1a and Supplementary Data). To prevent potential promoter competition, the pDIRE vector was designed such that *iCre* is expressed under the control of the *EF1A* promoter, while the expression of *Flpo* is controlled by the *PGK* promoter.

**Construction of the pDREV replacement vector series.** The H2B-Venus fusion protein was selected as a versatile and sensitive reporter because *Venus* is one of the brightest and best validated fluorescent proteins and the fusion of Venus with H2B<sup>7</sup> allows tracking of individual H2B-expressing cells *in vivo*. A 1.75-kb DNA fragment encoding *H2B-Venus* downstream of the autocleavable T2A peptide<sup>14</sup> and upstream of the SV40 pA site and the *rox*, *XhoI*, *rox* and *loxP* sites was synthesized by GeneArt and cloned as a *BglII*-*HindIII* fragment into the pL1L2\_GT vector series (B.R. and W.C.S., unpublished data) engineered in all three reading frames (Supplementary Fig. 1b). The *PGK-puro* selection cassette was excised as a *Sall* restriction fragment from the pPGKpuro plasmid (Addgene) and inserted into the *XhoI* site of the *L1L2-gt-H2B-Venus* plasmid series. This resulted in the definitive pDREV replacement vector collection (pDREV-0, pDREV-1 and pDREV-2), which is compatible with all three open reading frames (Supplementary Fig. 1b and Supplementary Data).

**Construction of the pDRAV replacement backbone vectors.** The pBluescript IKS plasmid was modified by inserting linkers to produce all possible orientations of the *loxP* and *FRT* sites together with a *lox2272* site that permits subsequent use of conventional RMCE. The *attB-pGK-Hygro-attP* resistance cassette was cloned into the *BamHI* and *Sall* sites. The multiple cloning sites of all pDRAV plasmids consist of unique *NotI*-*NsiI*-*HpaI*-*PacI*-*BamHI* restriction sites that can be used to insert the sequences of interest.

**Construction of the *Hand2*-Flag replacement vector (pRVH2).** Linkers were inserted into pBluescript IKS plasmid to produce the following restriction/recombinase site configuration: *SacI-loxP-NarI-NotI-BamHI-Sall-ClaI-FRT-HindIII-KpnI*.

A *NarI*-*NotI* fragment of the *Hand2* 5' untranslated region and a *NotI*-*BamHI* fragment corresponding to the remainder of the *Hand2* transcription unit (with a Flag-epitope tag inserted into coding exon 1) were sequentially inserted into the pBluescript IKS backbone. A DNA fragment encoding the *attB-pGK-hygro-attP* resistance cassette with *HindIII* and *PacI* sites (to enable Southern blot screening) was cloned into the *BamHI* and *Sall* sites of the pBluescript IKS backbone to produce the final replacement vector (Fig. 2a).

**Mouse embryonic stem cell transfection and selection.** 50 μg of the appropriate replacement vector were coelectroporated with 50 μg of pDIRE plasmid into mouse embryonic stem cells ( $1.5 \times 10^7$  cells per cuvette; 240 kV, 475 μF). IKMC mouse embryonic stem cells<sup>10</sup> were grown in Knockout DMEM (4.5 g l<sup>-1</sup> glucose) containing 10% FBS, 2 mM D-glutamine, 1× penicillin-streptomycin, 0.1 mM β-mercaptoethanol and 10<sup>3</sup> U ml<sup>-1</sup> LIF/ESGRO (Chemicon; all other reagents from Gibco-Invitrogen). R1 embryonic stem cells were grown in DMEM (4.5 g l<sup>-1</sup> glucose) containing 15% FCS (HyClone), 2 mM D-glutamine, 1× non-essential amino acids, 2 mM sodium pyruvate, 1× penicillin-streptomycin, 0.1 mM β-mercaptoethanol and 10<sup>3</sup> U ml<sup>-1</sup> LIF/ESGRO. The culture medium was changed daily and from the second day onward; resistant colonies were selected in the presence of 175 μg ml<sup>-1</sup> hygromycin or 0.5 μg ml<sup>-1</sup> puromycin (Sigma). After 8 d in selection medium, drug-resistant colonies were picked and analyzed by PCR. Clones with correct replacement were expanded, frozen in several aliquots and the correct replacement verified by Southern blot analysis. General protocols for handling, culture and manipulation of mouse embryonic stem cells are available as a standard textbook<sup>9</sup>. Detailed protocols for the culture of IKMC targeted mouse embryonic stem cells can be downloaded from the EUCOMM website (<http://www.eucomm.org/information/protocols/>).

**Immunodetection of YFP and β-galactosidase.** Embryonic stem cell colonies were grown on eight-well micro-Slides (Ibidi), fixed with cold acetone and incubated with rabbit anti-GFP-Alexa Fluor-488 (1:1,000; Invitrogen) and mouse anti-β-galactosidase (1:50; Developmental Studies Hybridoma Bank, Department of Biology, University of Iowa) primary antibodies, followed by an incubation step with a goat anti-mouse-Alexa Fluor-594 (1:1,000; Invitrogen). Fluorescent images were acquired using a Leica SP5 confocal microscope and software.

**Whole-mount *in situ* hybridization.** Mouse embryos were processed for whole-mount *in situ* hybridization using digoxigenin-labeled *Hand2* antisense riboprobes<sup>8</sup>. Images were acquired using a Leica MZ16A stereomicroscope and software.

**Image processing.** All images were processed and composites made using the Adobe Photoshop CS4 software package. Only contrast and brightness of the original images were adjusted minimally and within the linear range when necessary.

**Mice.** All animal experiments were performed in accordance with Swiss law and have been approved by the veterinary authorities of Basel.